# Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

> **NCT05735080** · PHASE1,PHASE2 · RECRUITING · sponsor: **Incyclix Bio** · enrollment: 150 (estimated)

## Conditions studied

- Breast Cancer
- Breast Cancer Metastatic
- Hormone Receptor Positive Tumor
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Ovarian Cancer
- CCNE1 Amplification
- Solid Tumor
- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** INX-315
- **DRUG:** Fulvestrant
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT05735080
- **Lead sponsor:** Incyclix Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-28
- **Primary completion:** 2027-07
- **Final completion:** 2027-09
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05735080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05735080, "Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05735080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*